Haywood analyst Gianluca Tucci maintained a Buy rating on WELL Health Technologies Corp (WELL – Research Report) yesterday and set a price target of C$8.50.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Gianluca Tucci has given his Buy rating due to a combination of factors that highlight WELL Health Technologies Corp’s strong financial outlook and strategic growth initiatives. The company is expected to report its Q1/25 results soon, and despite a recent adjustment due to a $6.5 million impact on revenue and adjusted EBITDA, WELL has shown robust underlying performance. This is evident from its solid Q4 results, which were affected by revenue deferrals but still demonstrated the company’s ability to meet its revenue and EBITDA guidance when adjusted for these deferrals.
Furthermore, WELL Health Technologies Corp has introduced optimistic guidance for 2025, projecting revenue between $1.4 billion to $1.45 billion and adjusted EBITDA between $190 million to $210 million. The company’s expansion efforts are also noteworthy, with the addition of 11 clinics during Q1/25, contributing $31.5 million in annualized revenue. This continued momentum in clinic-level expansion and the strong performance of its core Canadian business underpin Tucci’s positive outlook and Buy rating for the stock.
According to TipRanks, Tucci is a 4-star analyst with an average return of 10.4% and a 59.23% success rate.
In another report released yesterday, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a C$9.00 price target.